Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • drramki
    Junior Member
    • Dec 2010
    • 3

    Lower quality in reverse reads only. Is it normal?

    We did 100bp PE sequencing (RNA-Seq) on 8 samples and we see a distinct systematic drop in quality only for reverse reads (attached screenshots). We contacted the sequencing center and they said it "passed" their QC and also Illumina's spec of ~83% bases > q30. However, when we look at the % of sequences below q30, there is a remarkable difference (~7% in fwd reads vs ~24% in reverse reads).

    I wonder if this is okay. Similar problem has been discussed before in this forum or elsewhere.

    Bridged amplification & clustering followed by sequencing by synthesis. (Genome Analyzer / HiSeq / MiSeq)
    Attached Files
  • nucacidhunter
    Jafar Jabbari
    • Jan 2013
    • 1250

    #2
    Could you please post FastQC plot and which chemistry was used.

    Comment

    • GenoMax
      Senior Member
      • Feb 2008
      • 7142

      #3
      It is "normal" (if one wants to call it that) to see reduction in Q-scores in later R2 cycles (and the difference can be similar to what you found). I assume this is MiSeq data. As the sequencing center pointed out the data technically satisfies published spec for MiSeq Q-scores.

      One reason that can lead to rapid decrease in Q-scores is inserts shorter than the read length.

      Comment

      • drramki
        Junior Member
        • Dec 2010
        • 3

        #4
        Here is the link for fastQC plots. And I suppose this is MiSeq. We have never seen this pattern in HiSeq data.

        Comment

        • nucacidhunter
          Jafar Jabbari
          • Jan 2013
          • 1250

          #5
          If the read numbers are over 30M pairs/lane, it should be from HiSeq. In any case the quality drop is more than expected in any of Illumina systems and indicates an issue most likely with sequencing reagents. As GenoMax has pointed out short inserts also can be the cause where in later cycles adapter sequences are being read. It will be interesting to know output read number and % of reads which were demultiplexed.
          Last edited by nucacidhunter; 07-31-2014, 06:55 AM.

          Comment

          • drramki
            Junior Member
            • Dec 2010
            • 3

            #6
            Thanks GenoMax and nucacidhunter.

            I was wrong when I said MiSeq. This is actually from HiSeq. We got the data twice from the sequencing center and both looked same.

            Comment

            • GenoMax
              Senior Member
              • Feb 2008
              • 7142

              #7
              This may be a "not so good" quality library, if the result has been the same two times in a row on two runs. You would want to do some additional QC/cleanup (trimmomatic, bbduk etc) to figure out what is causing this drop (adapters?).

              Also ask the provider if they had seen something similar for other lanes on those runs to eliminate possibility of technical problems with the runs.

              Comment

              • nucacidhunter
                Jafar Jabbari
                • Jan 2013
                • 1250

                #8
                In addition to above suggestions you can have a look at Adapters plot in FastQC report to see the level of adapter sequences and if that correlates with drop in quality. Also you can check size distribution of the library by examining the Bioanalyser or TapeStation trace to work out insert sizes. If high percentage of library inserts is below 100 base (fragment sizes lower than 230 bp) in this case, the reads will run into adapters causing quality issues that can be fixed by trimming. If none of those seems to be likely cause it could be the chemistry specially if it was Rapid run.

                Comment

                • N311V
                  Member
                  • Jul 2013
                  • 34

                  #9
                  With pretty much all of our HiSeq data we do see a drop-off in quality towards the end of the second read but nothing that extreme. I tend to agree with previous comments that something has gone wrong here. In my experience sequencing centres etc. have rather soft QC metrics.

                  Comment

                  Latest Articles

                  Collapse

                  • SEQadmin2
                    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
                    by SEQadmin2


                    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

                    The systematic characterization of the human proteome has
                    ...
                    07-20-2026, 11:48 AM
                  • SEQadmin2
                    Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
                    by SEQadmin2



                    Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
                    ...
                    07-09-2026, 11:10 AM
                  • SEQadmin2
                    Cancer Drug Resistance: The Lingering Barrier to Rising Survival
                    by SEQadmin2



                    Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

                    There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
                    07-08-2026, 05:17 AM

                  ad_right_rmr

                  Collapse

                  News

                  Collapse

                  Topics Statistics Last Post
                  Started by SEQadmin2, Today, 12:17 PM
                  0 responses
                  10 views
                  0 reactions
                  Last Post SEQadmin2  
                  Started by SEQadmin2, Yesterday, 11:41 AM
                  0 responses
                  11 views
                  0 reactions
                  Last Post SEQadmin2  
                  Started by SEQadmin2, 07-20-2026, 11:10 AM
                  0 responses
                  23 views
                  0 reactions
                  Last Post SEQadmin2  
                  Started by SEQadmin2, 07-13-2026, 10:26 AM
                  0 responses
                  37 views
                  0 reactions
                  Last Post SEQadmin2  
                  Working...